EPMA position paper in cancer: current overview and future perspectives
| Autor: | Suzanne Hagan, Godfrey Grech, Byong Chul Yoo, Romano Danesi, Giorgio Vittadini, Xianquan Zhan, Rostyslav V Bubnov, Dominic M. Desiderio |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Context (language use)
Bioinformatics Cancer -- Treatment Quality of life (healthcare) Position Article and Guidelines Drug Discovery Health care Expert recommendation Medicine Biobank Biomarker Disease modeling Individual profile Multimodal diagnostics Predictive preventive personalized medicine Risk assessment Screening Standardization Health Policy Biochemistry (medical) Drug Discovery3003 Pharmaceutical Science Health policy business.industry Cancer -- Molecular diagnosis Cancer -- Risk factors Risk analysis (engineering) Position paper Personalized medicine business |
| Zdroj: | The EPMA Journal |
| ISSN: | 1878-5077 |
| Popis: | The authors acknowledge the contribution of Professor Olga Golubnitschaja for the critical discussion and advice in putting together the concept of the Position Paper. At present, a radical shift in cancer treatment is occurring in terms of predictive, preventive, and personalized medicine (PPPM). Individual patients will participate in more aspects of their healthcare. During the development of PPPM, many rapid, specific, and sensitive new methods for earlier detection of cancer will result in more efficient management of the patient and hence a better quality of life. Coordination of the various activities among different healthcare professionals in primary, secondary, and tertiary care requires well-defined competencies, implementation of training and educational programs, sharing of data, and harmonized guidelines. In this position paper, the current knowledge to understand cancer predisposition and risk factors, the cellular biology of cancer, predictive markers and treatment outcome, the improvement in technologies in screening and diagnosis, and provision of better drug development solutions are discussed in the context of a better implementation of personalized medicine. Recognition of the major risk factors for cancer initiation is the key for preventive strategies (EPMA J. 4(1):6, 2013). Of interest, cancer predisposing syndromes in particular the monogenic subtypes that lead to cancer progression are well defined and one should focus on implementation strategies to identify individuals at risk to allow preventive measures and early screening/diagnosis. Implementation of such measures is disturbed by improper use of the data, with breach of data protection as one of the risks to be heavily controlled. Population screening requires in depth cost-benefit analysis to justify healthcare costs, and the parameters screened should provide information that allow an actionable and deliverable solution, for better healthcare provision. peer-reviewed |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink